A new family of analgesic pharmaceuticals.
Invented in the USA.
The Elpis drugs are conjugate small molecules of three components -- a non-peptide:hinge:peptide -- forming what we call a "hybrid" chimera. These are molecules heretofore unknown to the scientific and medical literature of analgesia. Their design intent is for one moiety to activate the human mu opioid receptor as an agonist simultaneously with the activation by the other moiety of the human Substance P receptor as an agonist, with the hinge facilitating the simultaneity of action. We intend to develop, manufacture for testing, clinically test, and commercialize this family of new drugs, expected to provide opiate-analgesic (painkilling) relief without tolerance development. The Elpis project seeks to advance the science of analgesics so as to approximate or attain the "Holy Grail" of morphine analgesia without its undesirable side effects.
The chimeric hybrid, small molecules are expected to cross the blood/brain barrier and possess desirable analgesic properties akin to morphine without detrimental characteristics such as tolerance development. The lack of tolerance development will minimize or eliminate deleterious side effects, the need to escalate dosage and physical dependency formation and may alleviate the physical base that leads to psychological addiction. Such drugs would have the advantage of being administrable through means other than intrathecal administration, such as injection and perhaps oral administration.
Chimeracom has been issued a US patent (no. 6,881,829) for Chimeric Hybrid Analgesics. Preclinical testing is now underway on Elpis drugs comprised of a morphine moiety (an alkaloid) and a Substance P moiety (a peptide). Patents also pending in Europe, Japan, Russia and Eurasia, India, China, Canada, Australia, Brazil, Mexico, New Zealand, South Africa and Israel.
Read our Press Release about the award of our US Patent.
Our site is under construction. Watch for more information soon.
|
|
